The IL-17 family {#s2}
================

IL-17A, the founding member of the IL-17 family, was first discovered in mice in 1993 ([@bib161]) and 2 yr later in humans ([@bib200]). The IL-17 family is evolutionary conserved within vertebrates and composes six structurally related members in mammals, IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F ([@bib116]). All cytokines bind to their receptors as disulfide-linked homodimers, with the exception of IL-17A and IL-17F, which can also form heterodimers ([@bib194]; [Fig. 1](#fig1){ref-type="fig"}).

![**IL-17 cytokine and receptor family.** Schematic overview of the known heterodimeric IL-17 receptor complexes with their respective IL-17 cytokines. Unknown coreceptors and ligands are displayed with dashed lines. IL-17 receptors share a common structure with two extracellular fibronectin II--like (FN) domains and an intracellular SEFIR domain. Downstream signaling events depend on the adaptor Act1. In the canonical pathway Act1 ubiquitinates TRAF6, leading to recruitment of TAK1 and triggering of NF-κB, MAPK pathways, and the CCAAT-enhancer-binding proteins (C/EBP) pathway. The noncanonical pathway is initiated by phosphorylation of Act1 by inducible IκB kinase (IKKi) and the subsequent formation of a complex with TRAF2, TRAF5, and mRNA stabilizing factor human antigen R (HuR), which increases the half-life of several mRNAs. Ub, ubiquitin; P, phosphoryl group.](JEM_20191123_Fig1){#fig1}

Five IL-17 receptor subunits have been identified (IL-17RA, IL-17RB, IL-17RC, IL-17RD, and IL-17RE). All are single-pass transmembrane receptors with two extracellular fibronectin II--like domains and a cytoplasmatic "SEFIR" motif for activation of downstream signaling pathways ([@bib122]). The receptor for IL-17A and IL-I7F homodimers and IL-17A/F heterodimers consists of a heterodimeric receptor complex composed of IL-17RA and IL-17RC subunits. IL-17RA can also pair with IL-17RE or IL-17RB, which then bind IL-17C and IL-17E, respectively. IL-17B has been shown to engage with IL-17RB, but a coreceptor is still missing, as well as the cognate receptors for IL-17D and a cytokine that binds to IL-17RD.

IL-17R signal transduction has been best studied for IL-17RA/IL-17RC complexes after IL-17A ligation ([@bib59]). Receptor engagement leads to a conformational change, which allows the adaptor protein Act1 to form a homotypic interaction between the receptor's "SEFIR" domain and its own. The E3 ligase activity of Act1 initiates the canonical pathway via ubiquitylation of TNF receptor-associated factor 6 (TRAF6), recruitment of TAK1 and subsequent activation of the canonical NF-κB and MAPK pathways including ERK, p38, and JNK, as well as the CCAAT-enhancer-binding proteins pathway ([@bib133]). An alternative pathway depends on the phosphorylation of Act1 by inducible IκB kinase, which leads to the assembly of TRAF2 and TRAF5 with mRNA stabilizing factor human antigen R, thereby increasing stability of multiple mRNAs ([@bib6]). IL-17A and F lie in close proximity in the genome on chromosome 1 in mice and chromosome 6 in humans, share the highest structural identity among all IL-17 family members, and have been shown to have largely overlapping biological activities ([@bib4]; [@bib133]). Hereafter, we focus on IL-17A/F and their role in chronic inflammatory disorders and use IL-17 as shorthand.

T helper (Th) 17 cell polarization and other sources of IL-17 {#s3}
=============================================================

[@bib134] were the first to propose a bifurcation in CD4^+^ Th cells. Th1 cells were defined as mediators of "cellular immunity" directed against intracellular pathogens and were characterized mainly by their production of IL-2 and IFN-γ, but also other cytokines such as GM-CSF and TNF. Th2 cells were described as IL-4, IL-5, IL-13, and IL-10--secreting cells involved in "humoral immunity" directed against extracellular pathogens (reviewed in [@bib158]). The discovery of IL-17 initially did not influence the Th1/Th2 paradigm prevailing in the field at this time even though numerous reports indicated that it could be involved in several inflammatory disorders ([@bib94]; [@bib93]; [@bib7]; [@bib28], [@bib29]). [@bib101] found that among many other mediators, IL-17A is produced by Th cells upon engagement of their IL-23R. In vitro, IL-17 secretion could be elicited from naive CD4 T cells upon polarization with TGF-β and IL-6 ([@bib190]). In humans, IL-6 and IL-1β and IL-21 were later also identified as promoters of the IL-17 expression in Th cells (reviewed in [@bib163]). IL-17 expression is driven by the transcription factor RORγt (via a STAT3-dependent mechanism; [@bib74]). The term Th17 cell was coined, and for some time Th17 polarization and their role in immunity became the core interest of the immunology community. The discovery and characterization of Th17 cells are reviewed in more detail elsewhere ([@bib92]; [@bib120]). Over the years, it crystallized that the commonly called "IL-23/IL-17 axis" is critically involved in the regulation of tissue inflammation, in the context of both host defense and chronic inflammatory disorders.

In addition to Th17 cells, innate cells located at epithelial and mucosal barriers such as CD27^−^ γδ T cells, NK(T) cells, and innate lymphoid cells (ILCs) emerged as potent IL-17 producers ([@bib62]; [@bib50]; [@bib204]; [Fig. 2](#fig2){ref-type="fig"}). Their constitutive IL-23R and RORγt expression allows them to respond quickly (within hours) to injury or pathogenic triggers (reviewed in [@bib35]). Also, other leukocytes such as CD8 T cells and B cells and even Paneth cells have been reported as cellular sources of IL-17 ([@bib64]; [@bib168]; [@bib189]; [@bib180]; [Fig. 2](#fig2){ref-type="fig"}). Whether myeloid cells such as neutrophils or macrophages produce IL-17 is still controversially discussed (see [Fig. 2](#fig2){ref-type="fig"}).

![**Cellular sources and targets of IL-17A/F.** Overview of described cellular sources (top row) and targets (bottom row) of IL-17A/F. IL-23 induces IL-17 production in CD4 T cells ([@bib2]), γδ T cells ([@bib179]), NK(T) cells ([@bib132]; [@bib153]), ILCs ([@bib22]), and CD8 T cells ([@bib62]). The dependence of IL-23 on other IL-17--producing cells as Paneth cells ([@bib180]), mast cells ([@bib110]; [@bib117]), and B cells ([@bib168]) has to be determined. Whether myeloid cells (depicted in gray) produce IL-17 is still controversially discussed [@bib50]; [@bib175]; [@bib109]; [@bib181]. IL-17RA is ubiquitously expressed, but the main targets of IL-17 include endothelial cells, epithelial cells, fibroblasts ([@bib51]), osteoblasts ([@bib94]), and chondrocytes ([@bib172]). Less-studied potential cellular targets of IL-17 (depicted in gray) are myeloid cells and B and T cells.](JEM_20191123_Fig2){#fig2}

IL-17 is a pleiotropic cytokine that acts mainly on cells of mesenchymal origin such as endothelial cells, epithelial cells, and fibroblasts but has also effects on immune cells including dendritic cells and macrophages (reviewed in [@bib196]; [Fig. 2](#fig2){ref-type="fig"}). IL-17 executes key functions to prevent pathogen invasion by the secretion of proinflammatory cytokines, chemokines, matrix metalloproteinases, growth factors, and antimicrobial peptides (reviewed in [@bib145]). Hereby IL-17 often acts in synergy with other mediators such as TNF and IL-22 ([@bib173]; [@bib5]). Conversely, excessive IL-17 production contributes via similar mechanisms to pathogenic inflammation.

IL-17 in chronic inflammation {#s4}
=============================

Most of our understanding of IL-17 and its role in inflammatory disorders was gained through various preclinical models of disease and has prompted the development of new drugs targeting IL-17. Several drugs were designed to block the IL-17 pathway either selectively or in combination with other inflammatory cytokines, or cytokines involved in the maintenance of IL-17 producing cells such as IL-23. [Table 1](#tbl1){ref-type="table"} summarizes the therapeutic agents that are already approved or in clinical development. In the following section, we will discuss preclinical experimental findings about the role of IL-17 in prototypic chronic inflammatory disorders and compare the results to data from clinical trials.

###### Clinical development of IL-17/IL-23 inhibitors in chronic inflammatory diseases

                                                                                                          Barrier tissues                                      Nonbarrier tissues                                                                                                                                                                                                                                                                                                                                                    
  --------------------------------------------------------- --------------------------------------------- ---------------------------------------------------- ------------------------------------------------------------------- --------------------------------------------------------- ------------------------------------------------------------------- ----------------------------------------------------- -------------------------------------------------------------- ---------------------------------------------- --------------------------------------------------------------------------------
  IL-17A                                                    Secukinumab (AIN457; Cosentyx)                Approved                                             Phase II, terminated (ineffective); NCT01009281 ([@bib72])          Asthma: Phase II, terminated (ineffective); NCT01478360   Approved                                                            Approved                                              Phase III, terminated; NCT01377012                             Phase II, terminated; NCT01051817 ([@bib63])   Diabetes mellitus type 1: Phase II, terminated (business reasons); NCT02044848
  Atopic dermatitis: Phase II; NCT02594098                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Hidradenitis suppurativa: Phase II; NCT03713632           Giant cell arteritis: Phase II; NCT03765788                                                                                                                                                                                                                                                                                                                                                                                                                              
  Pityriasis rubra pilaris: Phase I; NCT03342573                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  IL-17A                                                    Ixekizumab (Taltz)                            Approved                                                                                                                                                                           Approved                                                            Phase III; NCT02696785 ([@bib187])                    Phase II; NCT00966875 ([@bib54])                                                                              
  IL-17A                                                    Netakimab (BCD-085)                           Phase III; NCT03390101                                                                                                                                                             Phase III; NCT03598751                                              Phase III; NCT03447704                                                                                                                                              Primary biliary cirrhosis: Phase II; NCT03476993
  IL-17A                                                    CNTO 6785                                                                                                                                                                                                                                                                                                                                                  Phase II (ineffective); NCT01909427 ([@bib129])                                                               
  IL-17A                                                    CJM112                                        Phase I, terminated; NCT01828086                                                                                         Asthma: Phase II; NCT03299686                                                                                                                                                                                                                                                                     
  Hidradenitis suppurativa: Phase II; NCT02421172                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  IL-17A /IL-17F                                            Bimekizumab                                   Phase III; NCT03598790                                                                                                   Hidradenitis suppurativa: Phase II; NCT03248531           Phase III; NCT03896581; NCT03895203                                 Phase III; NCT03928743                                                                                                                                              
  IL-17A/IL-17F                                             M1095 (ALX-0761)                              Phase II NCT03384745                                                                                                                                                                                                                                                                                                                                                                                                       
  IL-17RA                                                   Brodalumab (Siliq; Kyntheum)                  Approved                                             Phase II, terminated (disease worsening); NCT00966875 ([@bib183])   Asthma: Phase II, terminated (ineffective); NCT01902290   Phase III, terminated (sponsor decision); NCT02029495 ([@bib125])   Phase II, withdrawn (sponsor decision); NCT02429882   Phase II, terminated (ineffective); NCT00950989 ([@bib155])                                                   
  Phase II (ineffective); NCT01199289 ([@bib23])                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  IL-17A/TNF                                                ABT-122                                                                                                                                                                                                                          Phase II, (ineffective); NCT02349451 ([@bib128])                                                                          Phase II, (ineffective); NCT02433340, NCT02349451 ([@bib82])                                                  
  IL-17A/TNF                                                COVA 322                                      Phase II, terminated (safety profile); NCT02243787                                                                                                                                                                                                                                                                                                                                                                         
  IL-17/IL-6                                                MT-6194                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Preclinical ([@bib115])
  IL-17/BAFF                                                LY3090106                                                                                                                                                                                                                                                                                                                                                  Phase I; NCT01925157                                                                                          Sjögren's syndrome: Phase I; NCT02614716
  IL-23p19                                                  Risankizumab (Skyrizi)                        Approved                                             Crohn's disease: Phase III; NCT03104413, NCT03105102, NCT03105128   Asthma: Phase II; NCT02443298                             Phase III; NCT03675308, NCT03671148                                 Phase II (ineffective); NCT02047110 ([@bib9])                                                                                                                       
  Ulcerative colitis: Phase III; NCT03398148, NCT03398135   Atopic dermatitis: Phase II; NCT03706040                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Hidradenitis suppurativa: Phase II; NCT03926169                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  IL-23p19                                                  Tildrakizumab (Ilumetri; Ilumya)              Approved                                                                                                                                                                           Phase II; NCT03552276, NCT02980692                                  Phase III; NCT03552276                                                                                                                                              
  IL-23p19                                                  Guselkumab (Tremfya)                          Approved                                             Crohn's disease: Phase III; NCT03466411                                                                                       Phase III; NCT03796858, NCT03158285, NCT03162796                                                                          Phase II (ineffective); NCT01645280 ([@bib174])                                                               
  IL-23p19                                                  Brazikumab (AMG 139)                          Phase I; NCT01094093                                 Crohn's disease: Phase III; NCT03961815, NCT03759288                                                                                                                                                                                                                                                                                                                  
  Ulcerative colitis: Phase II; NCT03616821                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  IL-23p19                                                  Mirikizumab (LY 3074828)                      Phase III; NCT03535194                               Crohn's disease: Phase III; NCT03926130                                                                                                                                                                                                                                                                                                                               
  Ulcerative colitis: Phase II; NCT03524092                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

Source: <https://clinicaltrials.gov> if not otherwise specified. NCT, Clinicaltrials.gov identifier.

Targeting IL-17 in inflammatory disorders affecting skin and mucosal barriers {#s5}
=============================================================================

Psoriasis {#s6}
---------

Psoriasis is a chronic immune-mediated skin disease, characterized by the proliferation of keratinocytes and infiltration of T cells ([@bib140]). In xenograft models of psoriasis, nonlesional skin from psoriasis patients is transplanted onto immunocompromised mice ([@bib19]; [@bib21]). The model uncovered a pathogenic role of IL-23 ([@bib184]), IFN-α ([@bib139]), and TNF ([@bib21]) in psoriasis and paved the path for the successful introduction of TNF inhibitors as therapeutic options for psoriasis vulgaris ([@bib106]). In 2009, [@bib186] introduced the Aldara (5% Imiquimod)-model of psoriasis, which very closely mimics human psoriasiform lesions. We and others then found that psoriasiform inflammation greatly depends on the IL-23/IL-17 axis ([@bib149]; [@bib25]). Skin of Aldara-treated mice expressed high levels of IL-17A/F ([@bib149]; [@bib25]) and IL-22 ([@bib149]). In line with this, it was reported that IL-17A, IL-22, and IL-23 are up-regulated in the serum of patients with active psoriasis, and increased levels of IL-17A, F, and C were found in psoriatic skin lesions ([@bib76]; [@bib52]). Surprisingly, γδ T cells and not Th17 cells were found to be the primary source of IL-17A/F in the Aldara-mouse model, and their ablation led to disease protection ([@bib25]; [@bib149]). Similarly, increased numbers of IL-17 producing γδ T cells were also found in the skin of psoriasis patients ([@bib97]). There is some debate as to which cells in developing lesions initially deliver IL-17 as CD8^+^ IL-17 producing cells were also identified in psoriatic lesions ([@bib146]). The disease-promoting role of IL-17 in psoriasiform inflammation was shown to be mainly mediated via the activation of epithelial cells and keratinocytes and their increased secretion of antimicrobial peptides, cytokines, and chemokines mobilizing the recruitment of neutrophils (reviewed in [@bib156]).

After the identification of the IL-23/IL-17 axis as a key factor in the pathogenesis of psoriasis, Ustekinumab, the first p40 inhibitor targeting both IL-12 and IL-23, was introduced to the clinic with success ([@bib150]). However, we found that only IL-23 is disease-promoting in psoriasiform inflammation, whereas IL-12 has a protective role ([@bib95]), suggesting that collateral neutralization of IL-12 instead of IL-23 alone limited the effectiveness of these drugs.

Recently, the first three selective IL-23 inhibitors targeting the IL-23p19 subunit were licensed for treatment of plaque psoriasis after successful completion of several phase III clinical trials: Tildrakizumab, Risankizumab, and Guselkumab ([@bib159]; [@bib57]; [@bib16]). IL-23p19 inhibitors were more efficient in improving skin lesions than TNF inhibitors ([@bib159]) and in line with findings from the Aldara-model of psoriasiform inflammation, superior compared with IL-12/IL-23 inhibitor Ustekinumab ([@bib57]). The selective IL-23 inhibitor Guselkumab was also effective in psoriasis patients where combined IL-12/IL-23 inhibition had failed ([@bib99]), emphasizing that sparing IL-12 is necessary for resolution of skin inflammation in some psoriasis patients.

Between 2015 and 2017, three IL-17 pathway inhibitors reached the market. Secukinumab and Ixekizumab are monoclonal antibodies specific for IL-17A and thus inhibit both IL-17A homodimers as well as IL-17A/F heterodimers ([@bib112]), while IL-17F homodimers remain unaffected. In contrast, the monoclonal antibody Brodalumab targets IL-17RA, and thus blocks the activity of IL-17A, IL-17F, IL-17C, and IL-17E. All three biologicals are approved by the Food and Drug Administration and European Medicine Agency for the treatment of moderate to severe plaque psoriasis. Several pivotal phase III studies demonstrated rapid and sustained skin improvement in the treated patients compared with placebo ([@bib98]; [@bib56]; [@bib102]). Depending on the design of the studies, up to 42% of patients who received one of the IL-17 pathway inhibitors achieved disease-free skin ([@bib151]). Clinical responses are paralleled by decreased IL-17A, IL-17F, and IL-22 expression and downmodulation of leukocyte infiltration-promoting chemoattractants in the skin ([@bib87]).

IL-17 inhibitors showed superior efficacy in skin clearance than previously approved psoriasis therapy with IL-12/IL-23 inhibitor Ustekinumab ([@bib17]; [@bib154]; [@bib102]) or TNF inhibitor Etanercept ([@bib58]; [@bib98]). In addition, Ixekizumab demonstrated efficacy in Etanercept nonresponders ([@bib15]) and Brodalumab in Ustekinumab nonresponders ([@bib98]). Head-to-head trials comparing the efficacy between the available IL-17 and IL-23p19 inhibitors have not yet been performed, but a recent meta-analysis of 77 randomized controlled trials failed to detect a difference between the drug classes, as Brodalumab, Ixekizumab, Guselkumab, and Risankizumab were equally efficient to achieve skin improvement ([@bib167]).

Besides its presence in diseased skin, IL-17 is also observed in healthy skin and has a nonredundant role in tissue protection and immunity against fungi ([@bib135], [@bib136]; [@bib111]; [@bib144]; [@bib177]). In spite of this, the safety profile of IL-17 pathway inhibitors is favorable over long-term treatment with a consistent spectrum of adverse events across all three therapies ([@bib39]; [@bib100]; [@bib102]). Upper respiratory tract infections occur more frequently, followed by a higher susceptibility to mucocutaneous *Candida* spp. infections ([@bib166]).

We speculate that IL-17 production in cells associated with homeostasis in the skin is largely independent of IL-23R signaling, suggesting that the blockade of IL-23 would trigger fewer adverse effects compared with the general inhibition of IL-17, which may serve a function in homeostatic barrier maintenance and the control of the commensal flora. Indeed, the risk of *Candida* infections was lower when targeting IL-23p19 alone compared with studies with IL-17 inhibitors ([@bib18]). Whether IL-23 may be required for homeostatic IL-22 remains unclear.

Inflammatory bowel disease (IBD) {#s7}
--------------------------------

IBDs, which comprise of Crohn's disease and ulcerative colitis, are inflammatory conditions of the colon and small intestine ([@bib1]). Single nucleotide polymorphisms in *IL23R* are associated with the susceptibility to IBD, and both increased IL-23 and IL-17 levels were found in colon biopsies of IBD patients, especially during active disease ([@bib53]; [@bib42]; [@bib68]).

Also in mouse models of IBD, IL-23 was clearly associated with colitis, and as for psoriasis and experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis (MS), IL-23 and not IL-12 is critically driving the disease ([@bib22]; [@bib3]; [@bib201]; [@bib71]; [@bib45]). In contrast, targeting IL-17 or its receptors led to controversial results in different animal models of colitis. Already in 2004, [@bib143] showed that neutralization of IL-17 leads to increased disease severity in the dextrane sulfate sodium (DSS) model. Several studies confirmed this result in the DSS as well as in other models of IBD ([@bib142]; [@bib176]; [@bib104]; [@bib119]) and are in conflict with the few reports showing a disease promoting role of IL-17 ([@bib49]; [@bib108]; [@bib201]). Despite the description of a protective role of IL-17 in different murine models of colitis, IL-17A ([@bib72]) and IL-17RA inhibitors ([@bib183]) were tested for therapeutic efficacy in patients with Crohn's disease. The treatment failed and the studies had to be terminated due to exacerbation of colitis. In fact, it was already proposed in the early 2000s that IL-17 has an important role in the maintenance of barrier properties of epithelial tissues in vitro and later also in vivo ([@bib85]; [@bib104]). Two independent reports using different colitis models demonstrated that IL-17A increases the barrier integrity in epithelial cells and demonstrated that tissue-protective IL-17 is produced by γδ T cells in the absence of IL-23 (even though they do express IL-23R; [@bib104]; [@bib119]).

Interestingly, new-onset IBD is a rare adverse event in psoriasis patients treated with IL-17 inhibitors ([@bib169]), and mucosal inflammation is also not part of the disease spectrum in patients with inborn errors of the IL-17 pathway ([@bib144]). However, during an established mucosal inflammation like in Crohn's disease, the beneficial function of IL-17 on the integrity of the epithelial barrier might prevail ([@bib119]).

While IL-17 inhibition resulted in alarming disease exacerbation, IL-23 inhibition has revealed promising results in clinical trials for Crohn's disease ([@bib47], [@bib48]; [@bib164]). These clinical data suggest that selective targeting of IL-23 allows the IL-23--independent IL-17 production in the gut needed to keep the epithelial barrier intact, while IL-23--driven disease-promoting IL-17--producing cells decrease, mirroring results from previous animal studies ([@bib104]).

Given the critical role of IL-23 in the maintenance of disease-promoting IL-17--producing cells, selective IL-23 class inhibitors hold the promise to interfere especially with the development of these pathogenic IL-17--producing cells while sparing the IL-23--independent IL-17--producing cells involved in host defense against *Candida* and maintenance of the gut barrier. Several reports indicated that the protective effect of IL-17 could be mediated via the control of the commensal microflora ([@bib182]; [@bib176]; [@bib96]), which were already earlier shown to induce IL-17 in the colon ([@bib75]). Interestingly, disrupted IL-17R signaling in gut epithelial cells and the following dysbiosis was also connected to a higher predisposition to neuroinflammation, indicating that homeostatic IL-17R signaling in the gut is vital for a normal gut microflora, which in turn can control the autoimmune potential of lymphocytes ([@bib96]). Furthermore, it was shown that only deletion of IL-17F but not IL-17A prevents disease in both DSS and T cell--induced colitis models and that IL-17F promotes colitis by inhibiting the colonization of the gut by regulatory T cell--promoting commensals ([@bib182]). These findings indicate that specific IL-17F inhibitors also could be a potential option for the treatment of Crohn's disease.

[Fig. 3](#fig3){ref-type="fig"} summarizes the divergent roles of IL-23 and IL-17 inhibition in Crohn's disease and psoriasis.

![**Effects of targeting IL-17 and IL-23 in psoriasis and Crohn's disease.** The neutralization of IL-23 cures skin inflammation in psoriasis by interfering with the IL-23/IL-17 axis. Abrogation of pathogenic IL-23--dependent IL-17 production prevents IL-17--driven keratinocyte proliferation and neutrophil recruitment. IL-23--independent IL-17 production is preserved, which is needed for protection from *Candida* infections. Direct inhibition of IL-17 also reduces skin inflammation, but compromises host defense against *Candida*, leading to increased rates of candidiasis. Intestinal inflammation characteristic of Crohn's disease is improved upon IL-23 neutralization, which inhibits mainly IL-23--dependent IL-17 production and thus interferes with disease-driving mechanisms like neutrophil attraction. IL-23 neutralization spares IL-23--independent IL-17 production important for maintenance of epithelial barrier function and control of the commensal bacteria in the gut. In contrast, direct IL-17 inhibition exacerbates intestinal skin inflammation due to abrogation of the protective functions of IL-17 on epithelial integrity and microbiota control. This leads to invasion of luminal bacteria with a subsequent influx of immune cells and secretion of other pro-inflammatory cytokines to mount an immune response, which perpetuates intestinal inflammation.](JEM_20191123_Fig3){#fig3}

Other chronic inflammatory disorders afflicting barrier tissues {#s8}
---------------------------------------------------------------

The success of IL-17 inhibition in psoriasis encouraged the initiation of clinical trials in other chronic inflammatory diseases with elevated IL-17 expression. Serum IL-17 and IL-23 levels are increased in children with atopic dermatitis and correlated with disease severity ([@bib107]). IL-17 and IL-23 inhibitors are currently in phase II trials; however, two trails with the combined IL-12/IL-23 inhibitor Ustekinumab failed to show superiority compared with placebo ([@bib83]; [@bib162]), suggesting redundancy of the IL-23/IL-17 axis in atopic dermatitis. Several case reports reported successful outcomes of patients suffering from Hidradenitis suppurativa ([@bib77]) and Pityriasis rubra pilaris ([@bib193]) with IL-17 inhibitors, indicating shared pathomechanisms of these inflammatory skin diseases with psoriasis despite different clinical presentation. IL-17 pathway inhibition did not show a benefit over placebo for the treatment of asthma in multiple trials ([@bib23]; see [Table 1](#tbl1){ref-type="table"}), suggesting that the IL-23/IL-17 axis is not a major pathological driver in asthmatic airway inflammation.

Targeting IL-17 in inflammatory disorders affecting nonbarrier tissues {#s9}
======================================================================

Overexpression of IL-17 in mice leads to inflammation of epithelial barriers as well as granulocytosis ([@bib34]; [@bib61]). However, no inflammation-related symptoms of other, nonbarrier tissues are induced ([@bib61]). This argues against the notion that the dysregulation of IL-17 would elicit immunopathology in nonbarrier tissues. The exception seems to be psoriasis arthritis (PsA), where inflammation of the skin usually precedes joint pathology and has a very different disease etiology than rheumatoid arthritis (RA). Nevertheless, the role of IL-17 in inflammatory disorders of nonbarrier tissues was extensively studied using preclinical models, and IL-17 inhibitors were tested in the clinics.

PsA {#s10}
===

PsA is the most common psoriasis-associated disorder, found in up to 30% of psoriasis patients ([@bib160]; [@bib191]) and is among others associated to polymorphisms in *IL23R* ([@bib20]). Increased numbers of IL-17 producing ILCs as well as CD4 and CD8 T cells are found in the synovial fluid of PsA patients ([@bib12]; [@bib105]; [@bib131]). In the joints, IL-17 seems to act on osteoblasts inducing osteoclast differentiation and thereby increases bone resorption ([@bib165]). Until now, no specific murine model for has PsA existed. However, in some models for psoriasis, the development of arthritis was observed and demonstrated that changes in the skin can be sufficient to induce pathological changes in the joints ([@bib202]; [@bib197]; [@bib34]). In line with this, most drugs that are effective to treat psoriatic skin lesions also inhibit arthritis in PsA patients, indicating a shared pathophysiology ([@bib123], [@bib124]; [@bib126]). However, it is still unclear how inflammatory processes in the skin, which often precede PsA, lead to arthritis ([@bib43]).

Soon after the success in treating plaque psoriasis, Secukinumab and Ixekizumab received the Food and Drug Administration/European Medicine Agency approval for treatment of PsA ([@bib124]; [@bib127]); Secukinumab has extended the approved indication spectrum even for ankylosing spondylitis ([@bib8]). Both IL-17A inhibitors have shown clinical efficacy and long-term improvements, even in patients unresponsive to first-line therapy with TNF inhibitors ([@bib31]; [@bib138]). However, compared with the high rates of complete skin clearance in plaque psoriasis, effects on PsA are relatively modest, possibly due to a less pronounced IL-17 signature in affected joints compared with skin ([@bib11]). The safety profile in the setting of both diseases is comparable to IL-17 pathway inhibition in plaque psoriasis ([@bib130]; [@bib39]).

IL-23 inhibition is effective in phase II clinical studies in PsA ([@bib38]), and phase III studies are ongoing (NCT03552276), while there was no evidence of clinically meaningful improvements in ankylosing spondylitis ([@bib9]), although both diseases respond well to IL-17 blockade. A hypothesis for the dichotomy of clinical efficacy is that in contrast to PsA, IL-17--producing cells become IL-23--independent in the chronic phase of joint inflammation in ankylosing spondylitis as shown in an animal model ([@bib188]). Counterintuitive to the proposed synergistic action of TNF and IL-17A in PsA, a recent study failed to show superiority of dual neutralization of TNF and IL-17A with a bi-specific antibody over TNF inhibition alone ([@bib128]).

RA {#s11}
==

Early after the discovery of IL-17, several reports showed an association between IL-17 and RA, which is a systemic autoimmune disorder characterized by the chronic inflammation of several organs including the synovia of joints ([@bib170]). Those reports demonstrated the presence of IL-17 and IL-17R in synovial fluids and tissue from RA patients, and synovial IL-17 expression was identified as being predictive for joint damage progression ([@bib206]; [@bib69]; [@bib86]; [@bib29], [@bib28]). The main producers of IL-17 in synovial tissues of RA patients were identified as CD4^+^ memory T cells ([@bib94]). IL-17 was shown to potently induce cytokines such as TNF, IL-1β, and GM-CSF from different joint cells as synovial fibroblasts, chondrocytes, and macrophages ([@bib199], [@bib200]; [@bib51]; [@bib28]; [@bib78]) and was associated to bone and cartilage degradation ([@bib30]; [@bib24]; [@bib27]; [@bib84]; [@bib147]).

The disease-promoting role of IL-17 in RA was also described in mice. In wild-type mice, inflammatory arthritis can be induced by injecting recombinant IL-17 into the intra-articular space of knee joints ([@bib30]; [@bib24]). With rare exceptions ([@bib40]), the large majority of reports on IL-17 using different mouse models of RA showed that ablation of IL-17 reduced disease severity ([@bib113]; [@bib137]; [@bib79]; [@bib195]; [@bib65]; [@bib41]; [@bib30]). The ablation of IL-17 was associated with reduced systemic levels of IL-6 as well as IL-1β and RANKL (receptor activator of NF-κB ligand)--producing cells in the synovium ([@bib114]). Also, the transdifferentiation of Foxp3 regulatory T cells into IL-17--producing cells was associated to arthritis ([@bib88]). Furthermore, it was proposed that changes in the microbiome and IL-17 in the gut are early events in RA ([@bib195]), supporting the mucosal origins hypothesis suggesting that the disease-promoting immunity in RA is initiated at mucosal sites (leading to the circulation of auto-antibodies before clinical symptoms are observed) and only later spreads to the synovial joints generating symptomatic inflammation (reviewed in [@bib67]).

Despite the extensive rationale from preclinical studies in mice and human to target IL-17 in RA, results from clinical studies fell far short of expectations. Although IL-17A inhibition was superior to placebo and improved symptoms in TNF nonresponders ([@bib14]; [@bib54]), response rates were still lower compared with an established second-line biological CTLA4-Ig, Abatacept ([@bib14]). As these studies provided evidence that IL-17A is a central pathogenic driver only in a small subgroup of RA patients and other available substance classes are more effective, clinical development was terminated after phase III (NCT01377012).

Many of the preclinical findings on IL-17 in RA were made using the collagen-induced arthritis (CIA) model where DBA-1 mice are immunized against type 2 collagen and immune response is boosted with CFA ([@bib33]). Despite its valuable contributions to a better understanding of RA, in the CIA model, γδ T cells are the main producers of IL-17, while these cells were hardly detected in joints of RA patients ([@bib73]). We speculate that the CFA used in the CIA model induces the excessive IL-17 expression, thus inflating the role of IL-17 in the model compared with human RA.

Furthermore, it was recently shown that the transition of disease initiation to symptomatic arthritis could be mediated by IL-23 rather than IL-17. [@bib157] found that IL-23--activated Th17 cells promoted the production of pro-inflammatory antibodies by B cells via IL-22 and IL-21, but not IL-17. However, at least in established RA, a recent study with a selective IL-23 inhibitor showed no improvement in disease symptoms ([@bib174]).

MS {#s12}
==

As for other inflammatory disorders, dysregulated cytokines play an important role in MS. In 2002, it was shown that, as for psoriasis, IL-23 and not IL-12 is disease-promoting in the EAE model of MS ([@bib36]; [@bib10]). IL-23--deficient mice were shown to be resistant to EAE and had reduced levels of IL-17, while the transfer of IL-17--producing T cells led to disease exacerbation ([@bib101]). The presence of IL-17--producing cells in active brain lesions of MS patients ([@bib185]) and increased IL-17 levels in cerebrospinal fluid especially during clinical exacerbation ([@bib118]), supported the idea that IL-17 might be implicated in MS pathogenesis.

Surprisingly, blockade of IL-17A or F in EAE only led to a disease reduction in SJL/J mice, but had only a modest effect in C57/BL6 mice ([@bib152]; [@bib66]; [@bib89]; [@bib101]; [@bib61]). [@bib121] reported that IL-17--producing Th cells are only pathogenic when they are driven by IL-23, but not by IL-6 and TGFβ. In addition, IL-23 decreased the IL-10 expression by IL-17--producing cells, promoting their encephalitogenic capacity. In support of this, we found that IL-23 authorizes T cells to invade the central nervous system (CNS) and to polarize to Th17 cells ([@bib60]). Furthermore, several reports suggested the existence of nonpathogenic Th17 cells ([@bib198]; [@bib46]). All these findings demonstrate that while IL-23 is essential for the development of EAE, IL-17 is largely redundant for disease development, and IL-23 seems to induce other pathogenic mediators. Indeed, we and others reported that IL-23 converts nonpathogenic into pathogenic T cells by the induction of GM-CSF ([@bib32]; [@bib44]). Within the CNS of EAE mice, GM-CSF is produced almost exclusively by neuro-antigen--specific Th cells ([@bib90]), and systemic dysregulation of GM-CSF leads to severe and fatal CNS inflammation dominated by the invasion into the CNS of monocytes ([@bib178]). [@bib103] found that T-bet, which was already associated to the expression of IL-23R in Th17 cells ([@bib55]) and protection from EAE ([@bib148]), is driving the pathogenic functions of Th17 cells independently of their IL-17 production ([@bib103]). In line with this, clinically stable MS patients had higher expression of IL-10 in Th17 cells, and single-cell clones from patients with MS showed enhanced production of IL-17, GM-CSF, or IFN-γ, while in healthy controls, IL-10 dominated ([@bib26]; [@bib70]).

In summary, targeting of IL-17 does not efficiently inhibit disease formation in mice, whereas targeting IL-23 selectively blocks disease-promoting Th cells, independently of IL-17. The role of IL-17 in MS remains controversial. Although IL-17 pathway inhibition slowed down the formation of new Gd-enhancing T1 brain lesions in a phase II study, the trial was terminated because the cumulative number of lesions was not significantly different compared with placebo at the primary endpoint ([@bib63]). Although according to preclinical data the new selective IL-23 inhibitors offer a promising strategy for MS, clinical trials have not been initiated yet. Combined IL-12/IL-23 inhibition failed to show clinical efficacy in patients ([@bib171]; [@bib192]), possibly by a negative effect of the concomitant IL-12 pathway inhibition.

Other nonbarrier--associated chronic inflammatory diseases {#s13}
==========================================================

There are ongoing trials exploring the possibility of IL-17 inhibitors in primary biliary cirrhosis, giant cell arteritis, and Sjögren's syndrome ([Table 1](#tbl1){ref-type="table"}). The rational for such trials came from observations that IL-17--producing cells were present in the inflammatory infiltrates of the respective affected organs of patients ([@bib80]; [@bib37]; [@bib203]). A clinical trial investigating IL-17 inhibition in diabetes mellitus type 1 patients was terminated during phase II ([Table 1](#tbl1){ref-type="table"}).

Concluding remarks {#s14}
==================

It is becoming increasingly clear that dysregulated cytokine networks are fundamentally involved in chronic inflammatory diseases and that targeting cytokines therapeutically has great value in treating patients suffering from these disorders. Of note, excessive production of single cytokines in transgenic mice actually led to tissue-specific inflammation ([@bib81]; [@bib61]; [@bib178]). IL-17 in particular is connected with barrier function, and dysregulation of IL-17 is closely linked to psoriasiform skin inflammation. The most likely explanation for the skin tropism of IL-17--mediated inflammation is the fact that the receptor complex for IL-17 is highly abundant in the skin compared with other tissues. The normal steady-state function is likely the control of the commensal microflora, and as a quasi-innate cytokine, IL-17 can rapidly recruit other leukocytes in response to dysbiosis or pathogen invasion through barriers. So, neutralization of the IL-17/IL-23 axis has been shown to be beneficial in treating psoriasis, while in Crohn\'s disease only the targeting of IL-23 shows clinical benefit, possible because the steady-state function of IL-17 in gut barrier function is too fragile for external intervention. Nevertheless, the impact of the IL-23/IL-17 axis on the microbiome is abundantly clear. The nature of the commensal flora in the steady-state has in turn a dramatic effect on immunity in general. We thus propose that the conflicting data regarding the role of IL-17 in preclinical models of inflammation (outside of barrier tissues) is likely the result of the altered gut immune axis observed in IL-17--deficient mice. The clinical success of targeting the IL-17/IL-23 axis in chronic inflammation of the body lining but not of diseases of internal organs (e.g., RA, diabetes mellitus type 1, MS, etc.), was largely predicted in the preclinical studies, which provides further support for integrative and comprehensive bench to bedside research.
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